In Pearson v. Shalala, the court restricts FDA authority by allowing sellers of dietary supplements to make health claims based on less than “significant scientific agreement” when these claims are accompanied by a disclaimer. The authors raise issues regarding the lack of standards for substantiation and the effectiveness of disclaimers in light of the untested nature of some supplements and the vulnerabilities of some supplement consumers.
Get full access to this article
View all access options for this article.
References
1.
AndrewsJ. Craig, NetemeyerRichard G., and BurtonScot (1998), “Consumer Generalization of Nutrient Content Claims in Advertising,”Journal of Marketing, 62(October), 62–75.
2.
Dietary Supplement Health and Education Act (1994), Public Law No. 103–417, 108 Stat. 4325.
3.
Food and Nutrition Science Alliance (1997), “FANSA Releases Statement About Dietary Supplement Labeling,”Journal of the American Dietetic Association, 97(July), 782–83.
4.
Food Labeling & Nutrition News (1999), “Americans Call Federal Regulation of Dietary Supplements Inadequate,” (April 7), 12.
5.
FordGary T., HastakManoj, MitraAnusree, and RingoldDebra Jones (1996), “Can Consumers Interpret Nutrition Information in the Presence of a Health Claim? A Laboratory Investigation,”Journal of Public Policy & Marketing, 15(Spring), 16–27.
6.
FoxmanEllen R., MuehlingDarrel D., and MoorePatrick A. (1988), “Disclaimer Footnotes in Ads: Discrepancies Between Purpose and Performance,”Journal of Public Policy & Marketing, 7, 127–37.
7.
FunkhouserG. Ray (1984), “An Empirical Study of Consumers’ Sensitivity to the Wording of Affirmative Disclosure Messages,”Journal of Public Policy & Marketing, 3, 26–37.
8.
HatchOrrin G. (1994), “Congress Versus the Food and Drug Administration: How One Government Health Agency Harms the Public Health,”Journal of Public Policy & Marketing, 13(Spring), 151–54.
9.
HillRonald Paul, RampDavid L., and SilverLinda (1998), “The Rent-to-Own Industry and Pricing Disclosure Tactics,”Journal of Public Policy & Marketing, 17(Spring), 3–10.
10.
JacobyJacob, and HoyerWayne D. (1982), “Viewer Miscomprehension of Televised Communication: Selected Findings,”Journal of Marketing, 46(Fall), 12–26.
11.
JacobyJacob, and MorrinMaureen (1998), “‘Not Manufactured or Authorized by…’: Recent Federal Cases Involving Trademark Disclaimers,”Journal of Public Policy & Marketing, 17(Spring), 97–107.
12.
KinnearThomas C., TaylorJames R., and Gur-AurieOded (1983), “Affirmative Disclosure: Long-Term Monitoring of Residual Effects,”Journal of Public Policy & Marketing, 2, 38–45.
13.
MasonMarlys J. (1998), “Drugs or Dietary Supplements: FDA's Enforcement of DSHEA,”Journal of Public Policy & Marketing, 17(Fall), 296–302.
14.
MasonMarlys J., and ScammonDebra L. (1999), “Product and Brand Decisions in a Complex Information Environment: The Case of Supplements,” working paper, Department of Marketing, University of Utah.
15.
MoormanChristine, and PriceLinda L. (1989), “Consumer Policy Remedies and Consumer Segment Interactions,”Journal of Public Policy & Marketing, 8, 181–203.
16.
NeffJack (1998), “New World for Food Health Claims: Consumers, Government Both Appear Ready to Accept More Health-Related Food Claims,”Food Processing, 59(May), 66.
17.
PappalardoJanis K., and CalfeeJohn E. (1990), “What's Good in Theory Is Good in Practice: Using an Expected Value Rule to Regulate Health Claims,” in Enhancing Consumer Choice: Proceedings of the Second International Conference on Research in the Consumer Interest, RobertN. Mayer, ed. Columbia, MO: American Council on Consumer Interests, 79–95.
18.
Pearson v. Shalala (1999), 164 F.3d 650 (D.C. Cir.).
19.
Pharmanex Inc. v. Shalala (1998), 1998 U.S. Dist. LEXIS 7950, 97 Civ. 0262K (D. UT).
20.
SilvergladeBruce A. (1994), “The Vitamin Wars—Marketing, Lobbying, and the Consumer,”Journal of Public Policy & Marketing, 13(Spring), 152–54.
21.
StolbergSheryl Gay (1998), “Drug Regulators Make Push to Rein in Herbal Remedies,”The New York Times, (June 10), A1.
22.
WilkieWilliam L. (1982), “Affirmative Disclosure: Perspectives on FTC Orders,”Journal of Public Policy & Marketing, 1, 95–110.
23.
WilkieWilliam L. (1983), “Affirmative Disclosure at the FTC: Theoretical Framework and Typology of Case Selection,”Journal of Public Policy & Marketing, 2, 3–15.
24.
WilkieWilliam L. (1985), “Affirmative Disclosure at the FTC: Objectives for the Remedy and Outcomes of Past Orders,”Journal of Public Policy & Marketing, 4, 91–111.
25.
WilkieWilliam L. (1986), “Affirmative Disclosure at the FTC: Strategic Dimensions,”Journal of Public Policy & Marketing, 5, 123–45.
26.
WilkieWilliam L. (1987), “Affirmative Disclosure at the FTC: Communication Decisions,”Journal of Public Policy & Marketing, 6, 33–42.
27.
WrightAllison (1999), “FDA Tells Pearson Plaintiffs It Will Fully Comply with Federal Court Order on Health Claims,”Food Labeling & Nutrition News, (October 13), 1, 13–14.
